Genovis' Q3 release was a beat across the board showing growth, operating leverage and solid cash flow, with Genomics accelerating to its strongest quarter to date. While standing before tougher comparables in Q4, the business seems to have tailwind and the stock's valuation is not aligned with that. The stock now screens as 'Attractively priced' trading at a ~60% discount to Redeye's fair value.
LÄS MER
